{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:08:21Z","timestamp":1783145301525,"version":"3.54.6"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    The serrated neoplasia pathway is a major molecular route to colorectal carcinogenesis, accounting for approximately 15%\u201330% of sporadic colorectal cancers and characterized by early BRAF V600E mutation, CpG island methylator phenotype, and distinct histopathologic features. Although immune checkpoint inhibitors have shown clear efficacy in MSI-H\/dMMR colorectal cancer, serrated pathway\u2013associated tumors remain highly heterogeneous in their molecular evolution and immune microenvironments. This heterogeneity may be associated with diverse immune phenotypes and potentially variable responsiveness to immunotherapy. Emerging evidence suggests that changes in the immune microenvironment may begin before invasive transformation. In sessile serrated lesions, early immune surveillance features, including intraepithelial CD8\n                    <jats:sup>+<\/jats:sup>\n                    tissue-resident memory T cells, may be detectable before the development of a high tumor mutational burden state, whereas immune checkpoint upregulation and enrichment of regulatory immune populations indicate that adaptive immunosuppressive programs may arise in parallel. In this review, we synthesize evidence that immune alterations in serrated lesions are not merely accompanying features, but part of the biologic context in which lesions progress and later diverge. We therefore propose a stage-linked, hypothesis-generating framework in which early serrated lesions enter an immune-engaged yet counter-regulated state before later tending toward predominant inflamed MSI-H-like or immune-excluded MSS-like immune niches. Linking serrated lesions to changes in the immune microenvironment matters because it provides a biologic explanation for why morphologically similar precursor lesions may not be progression-equivalent and why advanced serrated-pathway cancers may diverge toward inflamed MSI-H-like or immune-excluded MSS-like states. Although not yet sufficient to alter classification or treatment selection, this perspective defines specific priorities for biomarker development, risk stratification, and mechanism-based therapeutic testing.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1830436","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:24:15Z","timestamp":1778473455000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Chenfei","family":"Jin","sequence":"first","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoze","family":"Liu","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zejun","family":"Wu","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Cui","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renkai","family":"Guo","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90186-i","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2002.02120.x","article-title":"The colorectal adenoma\u2013carcinoma sequence","volume":"89","author":"Leslie","year":"2002","journal-title":"Br J Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.161","article-title":"Serrated lesions of the colorectum: review and recommendations from an expert panel","volume":"107","author":"Rex","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1356250","article-title":"The histologic features, molecular features, detection and management of serrated polyps: a review","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084461","article-title":"Serrated colorectal lesions: an up-to-date review from histological pattern to molecular pathogenesis","volume":"23","author":"Mezzapesa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B7","volume-title":"Digestive system tumours","year":"2019"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1503\/cjs.018820","article-title":"Serrated polyps and polyposis of the colon: a brief review for surgeon endoscopists","volume":"64","author":"Hyun","year":"2021","journal-title":"Can J Surg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13000-020-01057-0","article-title":"Hyperplastic polyp or sessile serrated lesion? The contribution of serial sections to reclassification","volume":"15","author":"Jaravaza","year":"2020","journal-title":"Diagn Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5009\/gnl16523","article-title":"Sessile serrated adenomas: how to detect, characterize and resect","volume":"11","author":"Ma","year":"2017","journal-title":"Gut Liv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-255","article-title":"BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis","volume":"8","author":"Velho","year":"2008","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.08.038","article-title":"High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy","volume":"131","author":"Spring","year":"2006","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071017","article-title":"The molecular hallmarks of the serrated pathway in colorectal cancer","volume":"11","author":"De Palma","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s42003-023-05331-x","article-title":"BRAF(V600E)-mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism","volume":"6","author":"Rzasa","year":"2023","journal-title":"Commun Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2784","article-title":"A complex secretory program orchestrated by the inflammasome controls paracrine senescence","volume":"15","author":"Acosta","year":"2013","journal-title":"Nat Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.12.032","article-title":"Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7","volume":"132","author":"Wajapeyee","year":"2008","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.06.013","article-title":"Ink4a\/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis","volume":"18","author":"Bennecke","year":"2010","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.43","article-title":"Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps\/adenomas indicates a senescence barrier in the serrated route to colon cancer","volume":"24","author":"Kriegl","year":"2011","journal-title":"Mod Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201000099","article-title":"V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a","volume":"2","author":"Carragher","year":"2010","journal-title":"EMBO Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1515\/med-2020-0226","article-title":"Serrated lesions of the colon and rectum: emergent epidemiological data and molecular pathways","volume":"15","author":"Sacco","year":"2020","journal-title":"Open Med (Wars)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.260","article-title":"Magnitude, risk factors, and factors associated with adenoma miss rate of tandem colonoscopy: a systematic review and meta-analysis","volume":"156","author":"Zhao","year":"2019","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.034","article-title":"Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas\/polyps vary on the basis of center","volume":"12","author":"Payne","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.315","article-title":"Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort","volume":"105","author":"Hetzel","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.175","article-title":"Characteristics and survival of interval and sporadic colorectal cancer patients: a nationwide population-based cohort study","volume":"108","author":"Erichsen","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1912772117","article-title":"Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity","volume":"117","author":"Smit","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2015.0103","article-title":"Colorectal cancer carcinogenesis: a review of mechanisms","volume":"13","author":"Tariq","year":"2016","journal-title":"Cancer Biol Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.06.041","article-title":"Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia","volume":"157","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccr.2013.05.014","article-title":"A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention","volume":"24","author":"Rad","year":"2013","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor","volume":"6","author":"Copp\u00e9","year":"2008","journal-title":"PloS Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2019.03.12","article-title":"CpG island methylation in sessile serrated adenoma\/polyp of the colorectum: implications for differential diagnosis of molecularly high-risk lesions among non-dysplastic sessile serrated adenomas\/polyps","volume":"53","author":"Lee","year":"2019","journal-title":"J Pathol Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0280-2","article-title":"An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas","volume":"32","author":"Pai","year":"2019","journal-title":"Mod Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311849","article-title":"RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation","volume":"66","author":"Yan","year":"2017","journal-title":"Gut"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01997-x","article-title":"SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis","volume":"40","author":"Tong","year":"2021","journal-title":"Oncogene"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-02003-9","article-title":"Sessile serrated lesions with dysplasia: is it possible to nip them in the bud","volume":"58","author":"Utsumi","year":"2023","journal-title":"J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/path.5881","article-title":"The earliest events in BRAF-mutant colorectal cancer: exome sequencing of sessile serrated lesions with a tiny focus dysplasia or cancer reveals recurring mutations in two distinct progression pathways","volume":"257","author":"Bleijenberg","year":"2022","journal-title":"J Pathol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/his.12925","article-title":"Reappraisal of hMLH1 promoter methylation and protein expression status in the serrated neoplasia pathway","volume":"69","author":"Lee","year":"2016","journal-title":"Histopathology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/his.13851","article-title":"BRAF V600E immunohistochemistry demonstrates that some sessile serrated lesions with adenomatous dysplasia may represent collision lesions","volume":"75","author":"Bettington","year":"2019","journal-title":"Histopathology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab112","article-title":"Sessile serrated adenoma with dysplasia of the colon","volume":"157","author":"Batts","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12885-017-3946-5","article-title":"MLH1\u201393 G\/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF(V600E) mutation","volume":"18","author":"Fennell","year":"2018","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.08.020","article-title":"Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression","volume":"83","author":"Acosta-Gonzalez","year":"2019","journal-title":"Hum Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.11.031","article-title":"Differential pre-malignant programs and microenvironment chart distinct paths to Malignancy in human colorectal polyps","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcmgh.2022.10.001","article-title":"Single-cell transcriptomics reveals early molecular and immune alterations underlying the serrated neoplasia pathway toward colorectal cancer","volume":"15","author":"Zhou","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606184","article-title":"TGF\u03b2 signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype","volume":"8","author":"Fessler","year":"2016","journal-title":"EMBO Mol Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210923","article-title":"Retinoic acid signaling during priming licenses intestinal CD103+ CD8 TRM cell differentiation","volume":"220","author":"Qiu","year":"2023","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041022","article-title":"Challenges and therapeutic opportunities in the dMMR\/MSI-H colorectal cancer landscape","volume":"15","author":"Mulet-Margalef","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.211","article-title":"Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers","volume":"115","author":"Kim","year":"2016","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.95","article-title":"PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes","volume":"29","author":"Rosenbaum","year":"2016","journal-title":"Mod Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1445453","article-title":"Complex pattern of immune evasion in MSI colorectal cancer","volume":"7","author":"Ozcan","year":"2018","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.Cd-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000417","article-title":"B2M and JAK1\/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J Immunother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-21-4141","article-title":"Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade","volume":"82","author":"Jenkins","year":"2022","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","article-title":"IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy","volume":"19","author":"Du","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s12672-023-00718-y","article-title":"Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers","volume":"14","author":"Zhong","year":"2023","journal-title":"Discov Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i12.2129","article-title":"BRAF(V600E) mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs","volume":"13","author":"Zhi","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02483-9","article-title":"Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy","volume":"130","author":"Edin","year":"2024","journal-title":"Br J Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.ccell.2025.08.002","article-title":"Phase 1\/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF(V600E) metastatic colorectal cancer","volume":"43","author":"Morris","year":"2025","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/his.13874","article-title":"Loss of expression of MLH1 in non-dysplastic crypts is a harbinger of neoplastic progression in sessile serrated adenomas\/polyps","volume":"75","author":"Yozu","year":"2019","journal-title":"Histopathology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13148-019-0691-4","article-title":"DNA methylation changes that precede onset of dysplasia in advanced sessile serrated adenomas","volume":"11","author":"Liu","year":"2019","journal-title":"Clin Epigenet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.14740\/gr1062w","article-title":"Difference between left-sided and right-sided colorectal cancer: a focused review of literature","volume":"11","author":"Baran","year":"2018","journal-title":"Gastroenterol Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282017","article-title":"Influence of location-dependent sex difference on PD-L1, MMR\/MSI, and EGFR in colorectal carcinogenesis","volume":"18","author":"Choi","year":"2023","journal-title":"PloS One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/2326-6066.Cir-25-0481","article-title":"T-cell subset features and distributions evolve across the colorectal precancer-cancer spectrum","volume":"14","author":"Takashima","year":"2026","journal-title":"Cancer Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02882-6","article-title":"Spatial analysis by current multiplexed imaging technologies for the molecular characterisation of cancer tissues","volume":"131","author":"Semba","year":"2024","journal-title":"Br J Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13000-024-01571-5","article-title":"Concordance between immunohistochemistry and MSI analysis for detection of MMR\/MSI status in colorectal cancer patients","volume":"19","author":"Faizee","year":"2024","journal-title":"Diagn Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.41","article-title":"Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation","volume":"2","author":"Rau","year":"2016","journal-title":"J Pathol Clin Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.Capr-20-0592","article-title":"Immune responses vary in preinvasive colorectal lesions by tumor location and histology","volume":"14","author":"Wallace","year":"2021","journal-title":"Cancer Prev Res (Phila)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02483-9","article-title":"Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer \u2013 possible implications for immunotherapy","volume":"130","author":"Edin","year":"2024","journal-title":"Br J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1016\/j.cell.2022.09.027","article-title":"SnapShot: cancer immunoediting","volume":"185","author":"Varanasi","year":"2022","journal-title":"Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051149","article-title":"Immune checkpoint inhibition in metastatic colorectal cancer harboring microsatellite instability or mismatch repair deficiency","volume":"13","author":"Cohen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.02.019","article-title":"Resistance to immune checkpoint blockade: mechanisms, counter-acting approaches, and future directions","volume":"86","author":"Haddad","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403533","article-title":"Immune checkpoint inhibitors in colorectal cancer: limitation and challenges","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-1118-3","article-title":"BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer","volume":"10","author":"Deng","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/1897-4287-10-s2-a75","article-title":"Colorectal tumour BRAF V600E and MLH1 promoter methylation status in the assessment of mismatch repair gene sequence variants of unknown clinical significance","volume":"10","author":"Parsons","year":"2012","journal-title":"Hered Cancer Clin Pract"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152791","article-title":"MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: a systematic review and meta-analysis","volume":"216","author":"Wu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_349561","article-title":"The evolving treatment landscape in BRAF-V600E-mutated metastatic colorectal cancer","volume":"42","author":"Tabernero","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104497","article-title":"Colorectal cancer with BRAF V600E mutation: trends in immune checkpoint inhibitor treatment","volume":"204","author":"Liu","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae013","article-title":"The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"Jama"},{"key":"B88","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.754196","article-title":"Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00262-025-04005-3","article-title":"Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer","volume":"74","author":"Tak","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208900119","article-title":"MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas","volume":"119","author":"Stopfer","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i20.2452","article-title":"Serrated polyposis syndrome: molecular, pathological and clinical aspects","volume":"18","author":"Guarinos","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2022.101791","article-title":"Serrated polyposis syndrome; epidemiology and management","author":"Carballal","year":"2022","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000611","article-title":"Polyps and colorectal cancer in serrated polyposis syndrome: contribution of the classical adenoma-carcinoma and serrated neoplasia pathways","volume":"14","author":"van Toledo","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18030390","article-title":"Cancer prevention clinical trials: advances and challenges","volume":"18","author":"Francis","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-3168","article-title":"Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma","volume":"29","author":"Schoen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04182-9","article-title":"Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b\/2 trial","volume":"32","author":"D\u2019Alise","year":"2026","journal-title":"Nat Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/23808993.2025.2560303","article-title":"Immunotherapy for precision medicine in colorectal cancer","volume":"10","author":"Cao","year":"2025","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i7.106723","article-title":"Adoptive cell therapy in colorectal cancer: advances in chimeric antigen receptor T cells","volume":"17","author":"Chen","year":"2025","journal-title":"World J Gastrointest Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01784-5","article-title":"Cholesterol metabolism and colorectal cancer: the plot thickens","volume":"10","author":"Rzasa","year":"2024","journal-title":"Cell Death Discov"},{"key":"B101","doi-asserted-by":"publisher","first-page":"495","DOI":"10.37349\/etat.2024.00231","article-title":"Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair\/microsatellite instability: misdiagnosis, pseudoprogression and\/or tumor heterogeneity","volume":"5","author":"Normanno","year":"2024","journal-title":"Explor Targ Antitumor Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:24:21Z","timestamp":1778473461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1830436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":101,"alternative-id":["10.3389\/fonc.2026.1830436"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1830436","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1830436"}}